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Background: An increasing number of evidence suggests that pancreatic cancer contains cancer stem cells (CSCs),
which may be relevant to the resistance of chemotherapy. Latexin (Lxn) is a negative regulator of stem cell
proliferation and we investigate the effects of Lxn on CD133+ pancreatic cancer stem-like cells.
Methods: CD133+ miapaca-2 cells, a human pancreatic carcinoma cell line, were isolated and sorted by magnetic
activated cell sorting and flow cytometry. The capacity for self-renewal, proliferation, and tumorigenicity of CD133+
miapaca-2 cells was determined by the floating spheres test and tumor xenograft assays. Protein and mRNA
expression of Lxn in CD133+ and CD133- miapaca-2 cells were detected by Western blotting and qRT-PCR,
respectively. After CD133+ miapaca-2 cells were treated with Lxn in serum-free medium (SFM), cell proliferation
was assayed with a Cell Counting Kit 8 (CCK-8) and apoptosis was analyzed by flow cytometry. The protein and mRNA
expression levels of Bcl-2, bax, and c-myc were also analyzed.
Results: We successfully isolated CD133+ miapaca-2 cells that exhibited the capacity for self-renewal in SFM, a
proliferation potential in DMEM supplemented with FBS, and high tumorigenicity in nude mice. Lxn protein
and mRNA expression levels in CD133+ miapaca-2 cells were significantly lower than those in CD133- cells.
Lxn-treated CD133+ miapaca-2 cells exhibited increased apoptosis and low proliferation activity, down-regulation of
Bcl-2 and c-myc expression, and up-regulation of Bax expression in a dose-dependent manner.
Conclusions: Lxn induces apoptosis and inhibits the proliferation of CD133+ miapaca-2 cells. These changes are
associated with down-regulation of Bcl-2 and c-myc and up-regulation of Bax.
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Pancreatic cancer is a common malignant tumor of the
digestive system and the fourth most common cause of
cancer death [1]. Due to the lack of early diagnosis, the
propensity of early metastatic spread and the high resist-
ance to chemotherapy and radiation therapy, the prog-
nosis of pancreatic cancer remains poor, with the 5-year
survival rate being less than 5% [2]. There is increasing
evidence supporting a role for cancer stem cells (CSCs)
in the initiation, maintenance, proliferation, metastasis,* Correspondence: czz77@sina.com
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unless otherwise stated.and resistance to therapy of malignant tumors [3]. CSCs
have recently been reported in several types of solid tu-
mors, including pancreatic carcinoma [4-8]. Various cell
markers have been identified as markers for pancreatic
CSCs including CD44, CD24 and the epidermal surface
antigen (ESA) [4], CD133 [5], cxc chemokine receptor 4
(CXCR4) [5], c-Met [6], high activity of aldehyde dehydro-
genase 1 [7] and low activity of 26S proteasome [8]. Unfor-
tunately, none of the markers described as pancreatic CSC
markers are specific to pancreatic adenocarcinoma and
there is significant overlap with other cancer types and
even with healthy cells. CD133 has been a commonly used
marker for CSCs and several studies have reported that
CD133+ pancreatic cancer has some characteristics of
CSCs [5,9-11]. There is an increasing interest in searchingis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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for targeting this specific population of cancer cells.
Latexin (Lxn) is an antigen of 29 kDa expressed in a
subset of neurons in the rat cerebral cortex as well as in
various types of non-neural tissues such as heart, pros-
tate, ovary, kidney, pancreas, and colon [12,13]. As the
only known mammalian carboxypeptidase inhibitor, Lxn
shares 30% sequence similarity with tazarotene-induced
gene 1 (TIG1), which is down-regulated or absent in many
classes of tumors [14]. The loss of Lxn expression is asso-
ciated with an increased incidence of ovarian cancer,
leukemia and lymphoma [15]. Lxn expression is reduced
in human gastric cancers and hepatocellular carcinoma,
compared with normal control tissues [16,17]. Further-
more, Lxn negatively controls the hematopoietic stem cell
(HSC) populations in mice by decreasing cell replication
and increasing apoptosis [18,19]. More recently, Lxn has
been shown to inhibit melanoma cell proliferation and
down-regulate the expression of several stem cell tran-
scription factors, such as octamer-binding transcription
factor 4 (OCT4), sex determining region Y-box 2 (SOX2),
Kruppel-like factor 4 (KLF4), NANOG, and MYCN. This
evidence indicates that Lxn may indeed alter the stem
cell-like properties of melanoma cells [20]. The biological
effects of Lxn on pancreatic cancer stem-like cells, how-
ever, remain largely unknown.
The Bcl-2 family of proteins plays an important role
in the regulation of cell death and is comprised of both
pro-apoptotic (such as Bcl-x and Bcl-k) and anti-apoptotic
members (such as Bcl-2 and Bcl-xl). Defects in the
Bcl-2 family of proteins have been associated with chemo-
therapy resistance in various human cancers. Reduced
expression of anti-apoptotic members promotes apop-
totic responses to anticancer drugs, while increased ex-
pression of anti-apoptotic members such as Bcl-2 leads
to resistance to chemotherapeutic drugs and radiation
therapy [21].
Myc has a central function in stem cell biology. For
example, the transcription factor c-myc promotes the
proliferation and growth of cancer cells. Furthermore, its
dysregulation is often associated with advanced malig-
nancy and poor prognosis in diverse human cancers [22].
Civenni et al. reported that RNAi-mediated silencing of
Myc transcription inhibits stem-like cell maintenance and
tumorigenicity in prostate cancer [23]. More interestingly,
Bcl-2 activation and overexpression can inhibit apoptosis,
prolong cell survival, and reverse the pro-apoptotic effect
induced by c-myc [24]. Therefore, we speculated that the
Bcl-2 family and c-myc may play a crucial role in the pro-
liferation and apoptosis of CSCs.
The aim of the present study was to explore new strat-
egies for pancreatic cancer therapy. We tested the differ-
ential expression of Lxn between CD133+ pancreatic
cancer stem-like cells and CD133- pancreatic cancer cells.Furthermore, we investigated whether exogenous Lxn can
induce apoptosis and inhibit proliferation in CD133+ pan-
creatic cancer stem-like cells, and the mechanisms were
also studied. It is a meaningful effort to target this specific
population of cancer cells for pancreatic cancer therapy.
Methods
Cell sorting and cell culture
Human pancreatic cancer cell lines Aspc-1, panc-1, and
Bxpc-3 were obtained from the cell bank of the Chinese
Academy of Sciences (Shanghai, China). Human pancre-
atic cancer cell lines miapaca-2 and patu8988 were
purchased from the American Type Culture Collection
(ATCC; Manassas, VA, USA). All cells were maintained
in DMEM supplemented with 10% FBS (Gibco, Grand
Island, NY, USA), 100 units/mL of penicillin G and
10 μg/mL of streptomycin (Gibco, Grand Island, NY,
USA). The contents of CD133+ cells in the 5 human
pancreatic cancer cell lines were measured by flow cytom-
etry (FCM). CD133+ cells of the human pancreatic carcin-
oma cell line miapaca-2 were isolated by magnetic
activated cell sorting (MACS). A total of 5 × 107 miapaca-
2 cells were trypsinized, washed, and resuspended in
300 μL of PBS. After an addition of 100 μL of FcR block-
ing reagent, the cells were incubated in 100 μL of mono-
clonal CD133 antibodies labeled with MicroBeads
(Miltenyi Biotec Ltd, Bergisch Gladbach, Germany:
CD133/1; clone AC133, order number 130-050-801) for
30 minutes at 4°C. The CD133+ cells were enriched using
a MiniMACS magnet and MS columns (Miltenyi Biotech
Ltd, Bergisch Gladbach, Germany) and were flushed out
by applying the plunger supplied with the column. The
purity of CD133+ cells isolated from miapaca-2 cells
was determined by FCM analysis using a phycoeryth-
rin (PE)-labeled antibody against human CD133/2
(clone 293C3; Miltenyi Biotec Ltd, Bergisch Gladbach,
Germany, CD133/2(293C3)-PE, order number 130-090-
853). A PE-labeled antibody against mouse IgG2b was
used as an isotype. All procedures were performed accord-
ing to the manufacturers’ instructions. The FCM analysis
was performed using BD FACSAria (Becton, Dickinson
and Company, Franklin Lakes, NJ, USA). The data were
analyzed by Flowjo7.6.5 software (Tree Star Inc., Ashland,
OR, USA).
CD133+ and/or CD133- cells isolated by MACS were
seeded at a density of 1,000 cells/mL and cultured in
serum-free medium (SFM) containing DMEM/F12
(Gibco, Grand Island, NY, USA), 20 ng/mL of epidermal
growth factor (EGF; PeproTech Asia, Rehovot, Israel),
1% of B27 (Gibco, Grand Island, NY, USA), 0.4% of FBS
(Sigma-Aldrich, St. Louis, MO, USA), 5 μg/mL of bovine
insulin (Sigma-Aldrich, St. Louis, MO, USA, USA), and
100 U/mL of penicillin-streptomycin at 37°C in a hu-
midified atmosphere containing 5% CO2.
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All experimental procedures and protocols involving
animals were reviewed and approved by the Ethics
Committee of Wenzhou Medical University, Wenzhou,
China (number WYDW-20120008). Male athymic BALB/c
nu/nu mice (4 to 6 weeks old) were purchased from the
Shanghai Laboratory Animal Co. Ltd. (SLAC) (Shanghai,
China). CD133+, CD133- and unsorted miapaca-2 cells
were injected subcutaneously into the right anterior flank
of mice in various cell number totals (1 × 104, 1 × 105, and
1 × 106 in 150 μL PBS, respectively). The number of mice
exhibiting tumors was documented at 30 days after cell in-
jection. The animal protocol was designed to minimize
pain or discomfort to the animals. The animals were accli-
matized to laboratory conditions (23°C, 12 hours/12 hours
light/dark, 50% humidity, ad libitum access to food and
water) for 2 weeks prior to experimentation. All animals
were euthanized by barbiturate overdose (intravenous
injection, 150 mg/kg pentobarbital sodium) for tissue
collection.
Detection of apoptosis
CD133+ miapaca-2 cells in logarithmic phase were incu-
bated with different concentrations of Lxn (Abcam,Figure 1 The percentage of CD133+ cells in miapaca-2 and sorted
(293C3)-PE antibodies. The mouse IgG2b-PE antibody was used as an
CD133-PE, (C) Miapaca-2 CD133+ cells mouse IgG2b-PE (isotype), (D) MLondon, UK, ab87145; 0 ng/μL, 5 ng/μL, 10 ng/μL, 20 ng/μL
and 40 ng/μL) in SFM for 48 hours; cells of treated and
control groups were collected and digested with ethylene
diamine tetraacetic acid (EDTA) trypsinase. Cells were
collected, washed twice with ice-cold PBS, and then
precipitated by centrifugation at 500 g for 10 minutes;
the cell pellets were resuspended in 1 × Annexin V bind-
ing buffer. To a 100-μL aliquot of the cell suspension,
5 μL of Annexin V (20 μg/mL; Beyotime, Jiangsu, China)
and 5 μL of propidium iodide (PI; 50 μg/mL; Beyotime,
Jiangsu, China) were added, and the cells were incubated
in the dark for 15 minutes at room temperature (25°C).
Flow cytometry was performed using FACSCalibur
(Becton-Dickinson, San Jose, CA, USA). The data from a
total of 10,000 events were analyzed using CellQuest soft-
ware (Becton-Dickinson Immunocytometry Systems, San
Jose, CA, USA). The percentage of Annexin V-positive or
PI-positive cells was calculated.
Cell proliferation assay
A Cell Counting Kit 8 (CCK-8; Dojindo, Kumamoto, Japan)
was used to assay the antiproliferative activity of Lxn.
The cells were plated at a density of 5,000 cells per
well in 96-well plates containing SFM. Then, differentCD133+ cells determined by flow cytometry using CD133/2
isotype. (A) Miapaca-2 mouse IgG2b-PE (isotype), (B) Miapaca-2
iapaca-2 CD133+ cells CD133-PE.
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20 ng/μL, and 40 ng/μL) were added to the wells to a
final volume of 100 μL per well and incubated for 24 hours,
48 hours, and 72 hours. Subsequently, 10 μL of CCK-8
reagent were added to each well and incubated for 4 hours.
The optical density (OD) at a wavelength of 450 nm
was recorded using a microplate reader (ELX800; Bio-Tek,
Shoreline, WA, USA). All experiments were performed in
triplicate on three independent experiments.
qRT-PCR
Total RNA was isolated with TRIzol (Invitrogen, Carlsbad,
CA, USA) according to manufacturer's instructions. A
reverse transcription reaction was performed with a
ertAid™ First Strand cDNA Synthesis Kit from Fermentas
(Burlington, ON, Canada) using 2 μg of total RNA in a
final reaction volume of 20 μL. qRT-PCR was performed
with SYBR® Premix Ex Taq™ (perfect real time) PCR kit
from TaKaRa (Dalian, China) and the LightCycler 480
(Roche Biochemicals, Indianapolis, IN, USA). The primer
sequences were as follows: Lxn, sense 5’-GAAGGTCA
AACAAGCCAGCA-3’, antisense 5’-AACCCAGGCTA
AATGTAGAACG-3’; CD133, sense 5’-CACTTACGG
CACTCTTCACCTG-3’, antisense 5’-TGAAGTATCTT
GACGCTTTGGTAT-3’; Bcl-2, sense 5’-CGCAGAGG
GGCTACGAGT-3’, antisense 5’-GTTGACGCTCTCC
ACACACAT-3’; bax, sense 5’-TTTCTGACGGCAACTFigure 2 Proliferation ability of the CD133+ and CD133- cells in serum
and almost all cells died within 2 weeks (A). CD133+ cells formed floatin
supplemented with 10% FBS, the cells were adherent and proliferated
mRNA in CD133+ cells was dramatically higher than unsorted miapacaTCAACTG-3’, antisense 5’-CAACCACCCTGGTCTT
GGAT-3’; c-myc, sense 5’-GGTCTTCCCCTACCCTC
TCA-3’, antisense 5’-CTCCAGCAGAAGGTGATCCA-3’;
and β-actin, sense 5’-CGTGGACATCCGCAAAGAC-
3’, antisense 5’-AAGAAAGGGTGTAACGCAACTAA
G-3’. The qRT-PCR conditions were 30 seconds at 95°C,
followed by 45 cycles of 95°C for 10 seconds, and 60°C for
20 seconds. The melting curve analysis was performed to
verify product purity and exclude undesired primer di-
mers. All analyses were performed in triplicate in three in-
dependent experiments. The relative amount of target
gene mRNA was normalized to that of controls (β-actin).
Western blotting analysis
Harvested cells were washed with cold PBS and then lysed
with radioimmunoprecipitation assay (RIPA) Lysis Buffer
(Beyotime Bio, Haimen, China) containing 50 mM Tris
(pH 7.4), 15 mM NaCl, 1% Triton X-100, 1% sodium
deoxycholate, 0.1% sodium dodecyl sulfate (SDS) and pro-
tease inhibitors. The cell lysates were centrifuged at
12,000 g at 4°C for 20 minutes and the total proteins of
the supernatants were measured with a Beyotime BCA
Protein Assay Kit (Beyotime Bio, Haimen, China), accord-
ing to the manufacturer’s protocol. Equal amounts (30 μg)
of protein were electrophoresed on a 10% SDS-PAGE
gel and transferred to a polyvinylidene fluoride (PVDF)
membrane (Beyotime Bio, Haimen, China), which was-free medium. CD133- cells showed slow growth and good adherence;
g spheres (B). When the floating spheres were cultured in DMEM
similarly to unsorted miapaca-2 cells (C). The expression of CD133
-2 cells and re-adherence CD133+ cells (D). aP < 0.05.
Figure 3 Differences of tumor size and tumor weight between
CD133 +、CD133- and unsorted miapaca-2 cell groups.
(A) Tumor size of CD133+ cell groups were greater than that of
CD133- cell groups and unsorted miapaca-2 cell groups by naked
eye. (B) Tumor weight of CD133+ cell groups were more than that
of CD133- cell groups and unsorted miapaca-2 cell groups.
aP < 0.05, bP < 0.05.
Table 1 Tumorigenic ability of CD133+ cells, CD133- cells
and unsorted miapaca-2 cells
CD133+ cells CD133- cells Unsorted miapaca-2 cells
1 × 104 cells 9/10 0/10a 0/10b
1 × 105 cells 10/10 0/10a 4/10b
1 × 106 cells 10/10 4/10a 10/10
aP < 0.05, bP < 0.05 versus CD133+ cells.
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bodies: anti-Lxn antibody (Abcam, London, UK, ab103485,
diluted 1:500), anti-Bcl-2 antibody (Abcam, London, UK,
ab18210, diluted 1:1,000), anti-bax antibody (Abcam,
ab7977, diluted 1:1,000), anti-c-Myc (9E10) antibody
(Abcam, ab32, diluted 1:1,000), and anti-β-actin antibody
(Beyotime, Haimen, China, aa128, diluted 1:1,000).
Subsequently, the membrane was incubated at room
temperature for 2 hours with the following horseradish
peroxidase (HRP) labeled secondary antibodies: HRP-
labeled Goat Anti-Mouse IgG (Beyotime Bio, Haimen,
China, a0216, diluted 1:1,000) and HRP-labeled Goat Anti-
Rabbit IgG (Beyotime Bio, Haimen, China, aa208, di-
luted 1:1,000). The protein bands were detected by
enhanced chemiluminescence detection reagents (Applygen
Technologies, Beijing, China) and documented with
AlphaEaseFC 4.0 software (Alpha Innotech Co., San
Leandro, CA, USA).
Statistical analysis
Data are expressed as the mean ± SD. SPSS 16.0 for
Windows (SPSS Inc., Chicago, IL, USA) was used for
statistical analysis. Differences between treated groups
were analyzed with a one-way analysis of variance
(ANOVA). Fisher's exact probability was used to com-
pare the differences in categorized data. P < 0.05 was
considered statistically significant.
Results
Separation of CD133+ miapaca-2 and CD133- cells by
MACS and evaluation of the efficiency of sorting by flow
cytometry
The percentages of CD133+ cells in miapaca-2, aspc-1,
panc-1 cells, bxpc-3 and patu8988 cells were 1.18 ±
0.23%, 1.75 ± 0.45%, 1.24 ± 0.31%, 0.25 ± 0.13% and 0.29 ±
0.15%, respectively. To obtain CD133+ pancreatic can-
cer cells, a large number of cells are needed for MACS
because of the low proportion of CD133+ pancreatic
cancer cells. Miapaca-2 cells are easier to cultivate and
have a shorter cell growth cycle. We therefore chose
miapaca-2 cells for the following experiments. CD133+
and CD133- miapaca-2 cells were separated by MACS
and the purity of sorted CD133+ miapaca-2 cells was
found to be 94.45 ± 0.35% (Figure 1).
CD133+ cells in serum-free medium: formation of floating
spheres
We compared the proliferative capacity of CD133+ and
CD133- cells in SFM. Cells were cultured at a density of
1,000 cells/mL in 96-well plates for 7 days. As shown in
Figures 2A and B, the two populations of cells exhibited
different morphologies. CD133- cells exhibited markedly
slower proliferation, greater adherence, and a higher rate
of cell death after 1 week in culture. Under the sameculture conditions, the CD133+ cells formed floating
spheres (Figure 2B). After the floating spheres were har-
vested and gently disaggregated to a single cell suspen-
sion, the cells were cultured in DMEM supplemented
with 10% FBS 100 units/mL penicillin G and 10 μg/mL
of streptomycin. The cells were adherent and prolifer-
ated without significant differences from the unsorted
miapaca-2 cells (Figure 2C). Furthermore, the relative
level of CD133 mRNA in CD133+ cells was 7.15 ± 0.85,
which was dramatically higher than that in unsorted
miapaca-2 cells (0.14 ± 0.02; P = 0.000) and re-adherence
cells from the floating spheres (0.21 ± 0.03; P = 0.001;
Figure 2D).
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Nude mice were injected subcutaneously with CD133+
cells, CD133- cells or unsorted miapaca-2 cells at con-
centrations of 1 × 104, 1 × 105, or 1× 106, respectively (in
150 μL PBS). Tumorigenicity, as measured at 30 days
after cell injection, was significantly different among the
three types of cells: 1 × 104 CD133+ cells formed tumors,
1 × 106 CD133- cells and 1 × 105 unsorted miapaca-2
cells formed tumors in some mice, while 1 × 104 CD133-
cells or unsorted miapaca-2 cells failed to form tumors
(Table 1). The tumor weight (1.8 ± 0.52 g) of CD133+
cell groups was more than that of CD133- cell groups
(0.25 ± 0.16 g, P = 0.000) and unsorted miapaca-2 cell
groups (0.98 ± 0.41 g, P = 0.008; Figure 3). These results
indicated that CD133+ cells were associated with high
tumorigenicity.
The expression of Lxn in CD133+ and CD133- cells
The relative level of Lxn protein in CD133+ cells was
significantly lower than that in CD133- cells (0.35 ± 0.03
versus 0.89 ± 0.08; P < 0.05; Figure 4A, B). Similarly, the
relative level of Lxn mRNA in CD133+ cells was signifi-
cantly lower than that in CD133- cells (0.035 ± 0.003
versus 0.109 ± 0.012; P < 0.05; Figure 4C).
Effects of Lxn on apoptosis and cell growth in CD133+ cells
We determined the effects of Lxn on the rate of apop-
tosis in CD133+ cells relative to controls. As shown in
Figures 5B, C and D, the treatment of cells with Lxn forFigure 4 Lxn expression in CD133+ and CD133- cells. (A) The Lxn prot
CD133- cells. (B) The Lxn mRNA expression level in CD133+ cells was signi48 hours increased the percentage of early and late
apoptotic cells as well as necrotic cells in a dose-
dependent manner. On average, 22.8% of cells treated
with 40 ng/μL of Lxn were classified as necrotic cells or
late apoptotic cells.
We also determined the cell killing effects of Lxn on
CD133+ cells. As shown in Figure 6, with increasing Lxn
concentrations, its inhibitory effects on CD133+ cells in-
creased; the treatment with 5 ng/μL and 40 ng/μL of
Lxn for 48 hours resulted in a cell growth inhibition at a
rate of 10.5% and 31.2%, respectively. Similarly, the in-
hibitory effects on CD133+ cells increased as a function
of the incubation period. For example, treatment with
40 ng/μL of Lxn for 24 hours and 72 hours resulted in
cell inhibition rates of 23.8% and 47.4%, respectively.
Therefore, Lxn suppressed the proliferation of CD133+
cells in a time- and concentration-dependent manner.
Effects of Lxn on the expression of Bcl-2, bax, and c-myc
in CD133+ cells
As shown in Figure 7, Western blot analysis revealed
concentration-dependent decreases in Bcl-2 protein,
Bcl-2/bax ratio, and c-myc protein and an increase in
bax protein in CD133+ cells after treatment with Lxn.
Even a low concentration of Lxn (5 ng/μL) resulted in
the inhibition of Bcl-2 (0.81 ± 0.11 versus control, P =
0.021) and c-myc protein expression (0.85 ± 0.12 versus
control, P = 0.038). Moreover, treatment of cells with
40 ng/μL Lxn resulted in markedly greater reduction in
the expression of both proteins (0.44 ± 0.06 versus controlein expression level was decreased in CD133+ cells compared to
ficantly lower than that in CD133- cells. aP < 0.05.
Figure 5 Cell death analysis in CD133+ and CD133- cells. (A-D) Apoptosis of CD133+ miapaca-2 cells treated with 0 ng/μL (A), 10 ng/μL (B),
20 ng/μL (C) and 40 ng/μL (D) of Lxn. The lower left indicates live cells (Annexin V-FITC negative/PI negative); the lower right shows early apoptotic
cells (Annexin V-FITC positive/PI negative). The upper left shows damaged cells (Annexin V-FITC negative/PI positive), while the upper right
demonstrates necrotic cells and late apoptotic cells (Annexin V-FITC positive/PI positive). The number represents the percentage of early
apoptotic cells, necrotic cells, and late apoptotic cells in each condition (right quadrant). (E) The percentage of apoptotic cells, necrotic
cells, and late apoptotic CD133+ miapaca-2 cells treated with 0 ng/μL, 5 ng/μL, 10 ng/μL, 20 ng/μL and 40 ng/μL of Lxn. aP < 0.05, bP < 0.05,
cP < 0.05, dP < 0.05. FITC, fluorescein iodothiocyanate; PI, propidium bromide.
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respectively). Meanwhile, the expression of bax pro-
tein was significantly increased in the 10 ng/μL (3.28 ± 0.3,
P = 0.000) and 40 ng/μL (4.2 ± 0.4, P = 0.000) groups
compared with that of controls, and the Bcl-2/bax ratio
was decreased. Analogous to changes in protein expres-
sion, qRT-PCR analyses also showed a concentration-
dependent decrease in the expression of Bcl-2 (versus control,P < 0.05), Bcl-2/bax ratio (versus control, P < 0.05), and
c-myc mRNA (versus control, P < 0.05) and an increase
in the expression of bax mRNA levels (versus control,
P < 0.05) (Figure 8).
Discussion
CSCs are characterized by extensive self-renewal and pro-
liferative capacity as well as resistance to chemotherapy
Figure 6 Cytotoxic effects of Lxn treatment in CD133+ miapaca-2 cells treated with Lxn at various concentrations of Lxn. The inhibitory
ratio was calculated according to the following formula: Inhibitory ratio = (OD450 nm value of control group - OD450 nm value of Lxn treatment
group)/(OD450 nm value of control group - OD450 nm value of blank group). aP < 0.05, bP < 0.05, cP < 0.05, dP < 0.05.
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the initiation, maintenance and relapse of cancers [25].
The inability to effectively target CSCs is thought to con-
tribute to the failure of existing therapies [26]. In the
present study, we successfully isolated CD133+ miapaca-2
cells and demonstrated that they had some characteristics
of CSCs. Using these cancer stem-like cells, we further
demonstrated the effects of Lxn on the growth of these
cells and apoptosis, which were associated with the Bcl-2
family and c-myc. We believe that these results may be
useful in exploring novel therapeutic strategies for pancre-
atic cancer by targeting CSCs.Figure 7 The expression level of Bcl-2、c-myc and bax protein afte
of Bcl-2、c-myc and bax protein by Western blot analysis. (B) The relativ
to the controls. aP < 0.05, bP < 0.05, cP < 0.05, dP < 0.05.In the present study, we found that Lxn was decreased
in CD133+ cells compared to CD133- cells, suggesting
latexin may play a role in the suppression of pancreatic
cancer stem-like cells. To validate this point, CD133+
cells were treated with different concentrations of Lxn
protein. Our data indicated that Lxn increased cell
death. Lxn was originally identified in the lateral neo-
cortex of rats and serves as a marker of rationality
and development in rodent nervous systems. It acts as
a tissue or endogenous carboxypeptidase inhibitor in
humans [27]. It is reported that latexin negatively controls
the HSC populations in mice by decreasing cell replicationr treatment with Lxn in CD133+ cells. (A) The expression level
e expression level of Bcl-2、bax、bcl-2/bax and c-myc protein compared
Figure 8 The mRNA expression of Bcl-2 (A) and bax (B). The ratio of Bcl-2/bax (C) and c-myc (D). The relative amount of target gene mRNA
was normalized to β-actin and compared with the controls. aP < 0.05, bP < 0.05, cP < 0.05, dP < 0.05.
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cally expressed latexin in mouse lymphoma cells which
are lacking native latexin expression results in remarkable
suppression of cell growth [28]. The Lxn expression is re-
duced in human gastric cancers compared with their nor-
mal control tissues [16]. Lxn also inhibits gastric cancer
cell growth and tumorigenicity [16].
The Bcl-2 family plays a central role in the regulation
of cell death pathways including apoptosis, necrosis and
autophagy [29]. One of the major cell-death pathways,
namely the mitochondrial apoptotic pathway, is initi-
ated by mitochondrial outer-membrane permeabilization.
This, in turn, allows soluble proteins such as cytochrome
C in the mitochondrial inter-membrane space to diffuse
into the cytosol; thereby, engaging apoptotic protease acti-
vating factor-1 (APAF-1) to oligomerize into a caspase
activation platform termed apoptosome. Apoptosome
binds and promotes the activation of initiator caspase-9
and triggers a cascade of caspase (which are caspase-3,
caspase-6, and caspase-7) activation, resulting in the mor-
phologic and biochemical changes associated with apop-
tosis [30]. The overexpression of anti-apoptotic Bcl-2
family members has been associated with chemotherapy
resistance in various human cancers. Indeed, targeting theanti-apoptotic Bcl-2 family members can improve apop-
tosis and, thus, overcome drug resistance to cancer
chemotherapy [21]. The balance between anti-apoptotic
and pro-apoptotic Bcl-2 family members, rather than
mere overexpression of Bcl-2, regulates cancer cell death
[29]. In the present study, we evaluated changes in the ex-
pression of Bcl-2 and bax after treatment of CD133+ cells
with Lxn. We demonstrated a concentration-dependent
decrease in the expression of Bcl-2 at the protein and
mRNA levels and an increase in the expression of bax,
thereby resulting in a decrease in the ratio of Bcl-2/bax.
Our findings suggested that Lxn regulates apoptosis
and the proliferation of CD133+ miapaca-2 cells in a
manner that is dependent on the Bcl-2 family of proteins.
Future studies should examine the possible mechanisms
of action.
In the present study, we evaluated changes in c-myc
following treatment of CD133+ cells with Lxn, and dem-
onstrated a concentration-dependent decrease in c-myc
expression. These results indicated that Lxn regulates
CD133+ miapaca-2 cell apoptosis and proliferation via
c-myc. The proto-oncogene c-myc has been recognized
as an important regulator of stem cells, serving as a link
between malignancy and 'stemness' [31]. The activity of
Xue et al. World Journal of Surgical Oncology 2014, 12:404 Page 10 of 11
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of glioma cancer stem cells [32]. Future studies should
further examine the mechanisms responsible for the link
between Lxn, the Bcl-2 family and c-myc in CSCs.
Conclusions
The present study indicated that Lxn induces apoptosis
and inhibits the proliferation of CD133+ miapaca-2 pan-
creatic cancer stem-like cells' correlation to the Bcl-2
family and c-myc. Targeting Lxn may represent a new
therapeutic strategy for pancreatic cancer.
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